Mitigation of Non-Alcoholic Steatohepatitis via Recombinant Orosomucoid 2, an Acute Phase Protein Modulating the Erk1/2-PPARγ-Cd36 Pathway

The authors investigated the therapeutic potential of Orosomucoid 2, an acute phase protein predominantly secreted by hepatocytes, for treating non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.